Faculty & Staff at TUC

Alejandro Gugliucci

Alejandro Gugliucci

College: COM

Department: Administration, Research, Office of Sponsored Research

Title: Professor and Associate Dean for Research

Phone: (707) 638-5237

Fax: (707) 638-5255

E-Mail: alejandro.gugliucci@tu.edu

Office: Lander Hall Room 232D

Website: http://research.tu.edu/laboratories/gugliucci/index.html

Dr. Alejandro Gugliucci is a founding faculty member at Touro University, California, USA which he joined in 1997. He earned his MD and Board Certification in Laboratory Medicine from the University of the Republic, Uruguay. He obtained his PhD in Biochemistry at the University Louis Pasteur of Strasbourg, France. His postdoctoral fellowship in Cell Biology was carried out at the University of Montreal, Canada, where he also worked a few years as a faculty member before moving to the USA.


In his alma mater he was a professor in the Biochemistry and Clinical Pathology departments where he was Head of the Lipoprotein Metabolism division at 20-floor, 800 bed hospital for more than 10 years. He was a visiting professor in Tokyo Juntendo University and Niigata Medical School, Japan in 1998 and at the University of Sao Paulo, Brazil in 2007. He has been Full Professor of Biochemistry for the past 8 years. He served as COM Research Director then Associate Dean for Research for the past 10 years leading the exponential growth of research at TUC, the most significant in the Touro College system. He has been recently appointed as University Director of Research Development and Sponsored Programs. 


He has more than 30 years of experience in teaching of biochemistry, cell biology, physiology and clinical biochemistry, in 3 languages. Over the last 30 y over  6,000 medical students have received instruction from Dr Gugliucci. During his years in Canada he specialized in PBL.  At Touro he created and directed a Problem Based Learning program that ran for 8 years as well as a Laboratory Diagnosis course that also ran for 8 years. He also implemented and run an elective courses on Research Methodology and another Clinical Biochemistry for several years. He has authored 2 book chapters in Baynes's Medical Biochemistry, a textbook that will see its 4th Edition published in 2014.

His research interests lie on the role of glycation, oxidative reactions and the antioxidant enzyme paraoxonase on human disease, with a particular emphasis in diabetes, metabolic syndrome, obesity and atherosclerosis. Dr. Gugliucci is currently funded by 2 R01 grants from NIH and has been previously funded by the Canadian Diabetes Association, Asociation Diabete Quebec, NSERC (Natural Sciences and Engineering Research Council of Canada), Japan International Collaboration Agency, the Juvenile Diabetes Research Foundation, Pfizer and from intramural grants from Montreal, Canada and Touro Universities. He actively collaborates and publishes with faculty from UCSF, Hebrew University of Jerusalem, Showa, Kyoto and Jichi Universities, (Japan);  Reus University (Catalunya-Spain) and University of the Republic, Uruguay. He has published more than 80 articles in peer reviewed international journals, more than 180 abstracts and numerous invited reviews. He is a member of the Editorial Advisory Board for Life Sciences, Associate Editor of the Journal of Pediatric Biochemistry, a founding member of the International Maillard Reaction Society, where he serves in the Publications and Education Committee. He serves as ad hoc referee for more than 30 international journals.

University of the Republic, Uruguay MD Medicine 1983
University of the Republic, Clinical Pathologist Clinical Pathology 1988
Universite Louis Pasteur, Strasbourg, France PhD Biochemistry 1992
Universite de Montreal Post Doctoral Cell Biology 1993-1995

Integrated Systems

Endocrinology Unit

Biochemistry

Glycation, Oxidation, Disease Laboratory

Office of Sponsored Programs

The postgenomic and epigenetics era has already been launched, and glycation and oxidation (the Maillard reaction and free radical species attack) are one of the most important post-translational modifications of proteins in life science.

We head a lipidology laboratory that specializes in lipoprotein subclasses and their metabolic and atherogenic impact. Funded in part by NIH we study apoB48 and apoB100 particles kinetics in a study led by Dr Lustig in UCSF and Dr Schwarz at Touro.

Another major focus of our research is PON-1, a major antioxidant enzyme carried by HDL.


Finally we focus on the biochemistry and cell biology of diabetes mellitus chronic complications, with an emphasis on stochastic modification of proteins such as glycation (read more), oxidation and the action of reactive nitrogen species on proteins and lipoproteins. We are founding members of the International Maillard Reaction Society and authors of the glycation and disease webpage. more on glycation.


Our research covers several angles of these topics, ranging from cell biology to clinical studies and comprising research in cell culture systems, animal models and human subjects. We maintain active collaborations with other groups in the USA and across the globe with Japan, Israel (Hebrew University of Jerusalem), Brazil (University of Sao Paulo) and Uruguay.

Current funding:

Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency

NIH HL113887, R01                             Jean-Marc Schwarz, Ph.D. P.I.

                                                      Alejandro Gugliucci, MD. Ph.D.  Co-P.I.

Metabolic impact of fructose restrictions in obese children                        

NIH/NIDDK DK089216, R01                    Jean-Marc Schwarz, Ph.D. P.I.

                                                       Alejandro Gugliucci, MD. Ph.D.  Co-P.I.

 

Previous funding:

Intramural University of Montreal, 1996. Principal Investigator

Canadian Diabetes Association, 1995. Principal Investigator

National Science and Engineering Research Council, 1997-2001. Principal Investigator

Intramural Touro University, 2003-2004. Principal Investigator

Juvenile Diabetes Research Foundation, 2004-2005. Principal Investigator

NIH R01

Articles in Peer-Reviewed Journals

Recent publications (Last 5 years):

  • Menini T, Ikeda H, Kimura S, Gugliucci A. Circulating soluble RAGE increase after a cerebrovascular event. Clinical chemistry and laboratory medicine : CCLM / FESCC 2013:1-8.

  • Gugliucci A, Caccavello R, Kotani K, Sakane N, Kimura S. Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess HDL function. Clinica chimica acta; international journal of clinical chemistry 2013; 415:162-168.

  • Kotani K, Caccavello R, Mutou T, Yamada T, Taniguchi N, Gugliucci A. Association between reactive oxygen metabolites and paraoxonase 1 activity during a physical activity increase intervention with older Japanese people. Australasian journal on ageing 2012; 31:222-226.

  • Kotani K, Caccavello R, Taniguchi N, Gugliucci A. Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects. The Journal of international medical research 2012; 40:1878-1883.

  • Kotani K, Yamada T, Miyamoto M, Ishibashi S,
    Taniguchi N, Gugliucci A. Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients. Pharmacological reports : PR 2012; 64:212-216.

  • Munch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino acids 2012; 42:1221-1236.
  • Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. Journal of lipids 2012; 2012:726048.
  • Kotani K, Caccavello R, Sakane N, Yamada T, Taniguchi N, Gugliucci A. Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects. Journal of clinical medicine research 2011; 3:252-257.
  • Kotani K, Caccavello R, Sakane N, Miyamoto M, Gugliucci A. Influence of ezetimibe monotherapy on ischemia-modified albumin levels in hypercholesterolemic patients. Pharmacological reports : PR 2011; 63:1248-1251.
  • Kotani K, Kimura S, Kinugasa E, et al. Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease. The Journal of international medical research 2011; 39:1541-1545.
  • Kotani K, Kimura S, Gugliucci A. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. Journal of physiology and biochemistry 2011; 67:437-441.
  • Kotani K, Kimura S, Komada I, Sakane N, Gugliucci A. Continuous positive air pressure treatment reduces serum advanced glycation end products in patients with obstructive sleep apnoea syndrome: a pilot study. Primary care respiratory journal : journal of the General Practice Airways Group 2011; 20:336-337.
  • Gugliucci A, Kinugasa E, Kotani K, Caccavello R, Kimura S. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clinical chemistry and laboratory medicine : CCLM / FESCC 2011; 49:61-67.
  • Bracesco N, Sanchez AG, Contreras V, Menini T, Gugliucci A. Recent advances on Ilex paraguariensis research: minireview. Journal of ethnopharmacology 2011; 136:378-384.
  • Gugliucci A, Kotani K, Kinugasa E, Hermo R, Caccavello R, Kimura S. Serum aspirin esterase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after haemodialysis. Annals of clinical biochemistry 2010; 47:559-563.
  • Kotani K, Kimura S, Ebara T, Caccavello R, Gugliucci A. Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus. Diabetology & metabolic syndrome 2010; 2:50.
  • Kotani K, Caccavello R, Hermo R, Yamada T, Taniguchi N, Gugliucci A. Serum cholesterol concentration associated with aspirin esterase activity in older people: preliminary data. International journal of medical sciences 2010; 7:90-93.
  • Gugliucci A. Beyond the antioxidant properties: pomegranate juice polyphenols increase hepatocyte paraoxonase 1 secretion. Atherosclerosis 2010; 208:28-29.
  • Kotani K, Adachi S, Tsuzaki K, Sakane N, Gugliucci A. The association between resistin, high-density lipoprotein cholesterol and carotid atherosclerosis in elderly women with hypertension. International journal of cardiology 2010; 141:193-194.
  • Kotani K, Sakane N, Sano Y, et al. Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. Journal of clinical biochemistry and nutrition 2009; 45:329-334.
  • Gugliucci A. "Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? Medical hypotheses 2009; 73:921-924.
  • Gugliucci A, Kotani K, Taing J, et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Annals of nutrition & metabolism 2009; 54:197-201.
  • Gugliucci A, Bastos DH, Schulze J, Souza MF. Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia 2009; 80:339-344.
  • Gugliucci A, Bastos DH. Chlorogenic acid protects paraoxonase 1 activity in high density lipoprotein from inactivation caused by physiological concentrations of hypochlorite. Fitoterapia 2009; 80:138-142.
  • Gugliucci A, Schulze J, Kinugasa E, Ogata H, Kimura S. The free fraction of paraoxonase 1 is not increased in patients with end stage renal disease undergoing hemodialysis. Clinica chimica acta; international journal of clinical chemistry 2009; 402:209-210.
  • Gugliucci A. Hypochlorous acid is a potent inactivator of human plasminogen at concentrations secreted by activated granulocytes. Clinical chemistry and laboratory medicine : CCLM / FESCC 2008; 46:1403-1409.
  • Gavazza A, Lubas G, Valori E, Gugliucci B. Retrospective survey of malignant lymphoma cases in the dog: clinical, therapeutical and prognostic features. Veterinary research communications 2008; 32 Suppl 1:S291-293.
  • Kotani K, Kimura S, Tsuzaki K, et al. Reduced paraoxonase 1/arylesterase activity and its post-therapeutic increase in obstructive sleep apnea syndrome: a preliminary study. Clinica chimica acta; international journal of clinical chemistry 2008; 395:184-185.
  • Gugliucci A. Antithrombin activity is inhibited by acrolein and homocysteine thiolactone: Protection by cysteine. Life sciences 2008; 82:413-418.

 

FELLOWSHIPS

Research fellow of the Japan International Cooperation Agency (JICA)
Research fellow of France, Foreign Affairs Office FRANCE
Research fellow (post Doc) Canadian Diabetes Association


VISITING PROFESSORSHIPS

Japan. 1988. Clinical Pathology. Universities of Juntendo, Tokyo and Niigata.

Visiting Professorship, Fellow of the Japan International Cooperation Agency (JICA)

France. 1993. Biochemistry. Université Louis Pasteur of Strasbourg, UFR des Sciences Pharmaceutiques, Dept de Biochimie

ACTIVE MEMBERSHIPS

American Diabetes Association Professional section

Founding Member International Maillard Reaction Society. IMARS website

EDITORIAL BOARD

Member of the International Editorial Board of LIFE SCIENCES
Member of the International Editorial Board of IMARS News

Employer Title From - To
University of the Republic, Uruguay Lecturer-Assistant Professor, Biochemistry and Clinical Biochemistry 1978-1988
Universite Louis Pasteur, Strasbourg, Farnce Visiting Professor 1992-1993
Juntendo University, Tokyo, Japan Visiting Professor 1988
Universite de Montreal, Montreal, Canada Assistant Professor 1995-1997
Touro University Assistant Professor 1997-2000
Touro University Associate Professor 2000-2005
Touro University Professor 2005-
Touro University Research Director COM 2004-2008
Touro University Associate Dean Research COM 2008-
Touro University University Director of Research Development and Sponsored Programs 2012-
Last Updated: 3/15/16